Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This study is divided into Part I and Part II. Part I is the food effect study. A total of 20
healthy subjects, regardless of gender, will be enrolled in a randomized, open-label,
crossover design.
Part II is the drug-drug interaction study, an open-label and sequential design. 32 healthy
subjects are planned to be enrolled and divided into group A and group B. Group A is to
evaluate the influence of itraconazole as CYP3A4 strong inhibitory on HLX208. Group B was to
evaluate the effect of rifampicin as a strong inducer of CYP3A4 on HLX208.